Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cAPPricorn-1: ALN-APP in Cerebral Amyloid Angiopathy
NCT06393712Phase 2Active, not recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- May 2024
- Primary completion
- Aug 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 6
01
Overview
A Phase 2 trial of mivelsiran in cerebral amyloid angiopathy (CAA), sponsored by Alnylam Pharmaceuticals. Started May 2024; status: active, not recruiting.
02
Drugs
mivelsiran
03
Conditions
cerebral amyloid angiopathy (CAA)
Beyond the preview
Go deeper on NCT06393712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06393712.